Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Learn effective ways to use cash back for travel expenses and enhance your travel budget, making your trips more affordable and enjoyable.
23,036 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
AI-driven demand and easing supply bottlenecks push chipmakers into the spotlight. Here’s a timely look at the best s...
Tesla enters a pivotal period as AI-driven software and energy products meet traditional EV growth. This article asse...
A new Allianz study shows Gen X is the cohort most worried about taxes in retirement, with rising fears about how tax...
Nuclear energy stocks are poised for renewed interest in 2026 thanks to reliability, carbon-free power, and policy ta...
When a major investor dumped million from a high-yield closed-end fund, it sent a clear message about risk, liquidity...
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
New data place the Appalachian belt at the center of Lithium supply debates, but real-world timelines and costs may s...
A deal of this size reshapes risk, rewards, and portfolio strategy. Here is the thing investors should know and pract...
Warren Buffett's successor, Greg Abel, is drawing new attention as recent 13F filings hint at a shift in Berkshire's ...
A little-known income ETF has doubled this year by selling covered calls on AMD, outperforming the broad market as th...
Meta Platforms trades near the $630s as investors weigh AI-driven capex against margin gains. A growing capital bill ...